# DEWI (NCT06059495)

> DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06059495
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
- Conditions: Adenocarcinoma - GEJ; Gastric Adenocarcinoma
- Interventions: Dostarlimab
- Enrollment: 89
- Primary outcome: Clinical complete response (cCR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 7

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=dewi-nct06059495